Lilly to launch real-world Covid-19 study of bamlanivimab in New Mexico
Eli Lilly and Company (Lilly), a global leader in the pharmaceutical industry, has announced plans to conduct a new pragmatic study of its experimental Covid-19 ... Read More
Lilly partners with UnitedHealth Group for pragmatic study of bamlanivimab in high-risk COVID-19 patients
Eli Lilly and Company (Lilly) has formed a strategic collaboration with UnitedHealth Group to conduct a pragmatic clinical study on bamlanivimab (LY-CoV555), a monoclonal antibody ... Read More
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA
The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly ... Read More
Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt
Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, ... Read More
Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies
Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. ... Read More
Lilly begins phase 1 coronavirus antibody trial with LY-CoV555
Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed in a phase 1 clinical trial with ... Read More